Capital Analysts LLC
TAK icon

Capital Analysts LLC’s Takeda Pharmaceutical TAK Stock Holding History

Capital Analysts LLC’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-145
Closed -$2K – 1028
2021
Q4 		$2K Hold
145
– – ﹤0.01% 959
2021
Q3 		$2K Hold
145
– – ﹤0.01% 935
2021
Q2 		$2K Hold
145
– – ﹤0.01% 892
2021
Q1 		$3K Buy
+145
New +$2.61K ﹤0.01% 935

Other funds holding TAK

Parametric Portfolio Associates
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Capital Analysts LLC's TAK Position: Q1 2022 in Review

Capital Analysts LLC sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 145 shares — an estimated $2K sold.

Capital Analysts LLC first reported a position in TAK in Q1 2021 and held it in 4 quarters. The position peaked at $3K in Q1 2021. 288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

  • Capital Analysts LLC reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
  • Capital Analysts LLC sold 145 Takeda Pharmaceutical shares in Q1 2022, an estimated $2K.
  • Capital Analysts LLC first reported a position in Takeda Pharmaceutical in Q1 2021 and held it in 4 quarters.
  • Capital Analysts LLC's Takeda Pharmaceutical position peaked at $3K in Q1 2021.
  • 288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on Capital Analysts LLC's 13F filing for Q1 2022, filed 12 May 2022.